Clinical Trials

Insilico Medicine has reached a significant clinical milestone with the completion of first-in-human dosing of ISM8969 in a Phase 1 study. Conducted in collaboration with Hygtia Therapeutics, the ISM8969 Phase 1 trial marks the transition of this oral, brain-penetrant...

German pharmaceutical company Boehringer Ingelheim has reported that its experimental obesity drug, survodutide, significantly reduced visceral abdominal fat and liver fat while largely preserving lean body mass in a late-stage clinical study. The data strengthens the company's argument that...

MSD and Adcendo have established a collaboration and supply agreement to evaluate the combination of ADCE-T02 and pembrolizumab. The companies are preparing for a Phase Ib solid tumour clinical trial targeting patients with advanced solid tumours. Adcendo will act as...

The global Decentralized Clinical Trials Market is expected to grow from USD 9.74 billion in 2025 to USD 34.13 billion by 2035, registering a compound annual growth rate (CAGR) of 13.36% during the forecast period from 2026 to 2035....

In a strategic move to bolster the national pharmaceutical industry, the Algerian Minister of Pharmaceutical Industry, Mr. Wassim Kouidri, convened with the Ambassador of the Republic of Hungary, Mr. Gábor Levente Szarka, this Sunday in Algiers. The high-level discussions...

The modernization of clinical development is undergoing a massive shift as quantum-based optimization tools are integrated into trial architectures. By improving patient selection and simulating physiological responses at a molecular level, these technologies are reducing the high failure rates associated with traditional research phases. This evolution toward digital and adaptive trials ensures that therapeutic candidates are tested more efficiently, leading to faster regulatory approvals and a more streamlined path for delivering life-saving treatments to the public.

The U.S. Food and Drug Administration has unveiled a new regulatory initiative to enable real-time clinical trials, marking a structural shift in how drug development data is reviewed. The program, already supported by AstraZeneca and Amgen, introduces a model...